Prediction of new varieties: 25 high quality varieties that are expected to reconstruct the market

Before that, after the adjustment of the 2009 version of the medical insurance catalog, a number of large-scale varieties were born, such as entecavir, rat nerve growth factor, rosuvastatin, edaravone, and butylphthalide According to the results of the new edition of the medical insurance catalog, this paper mainly analyzes the high-quality varieties of high-quality pharmaceutical enterprises According to the data of sample hospitals, 25 newly added medical insurance products were selected for analysis, involving more than 60 pharmaceutical enterprises in total Domestic enterprises mainly involve stone medicine, Hengrui, hausen, Qilu, Zhongxin Guojian, Beida, Tianqing, Guizhou Baiqiang, Lizhu, etc., while foreign enterprises include Novartis, asilikang, Lilai, etc The main products of antitumor drugs are pemetrexed, imatinib, gefitinib, doxorubicin, exetinib, compound sodium cantharidate vitamin B6 and desetabine According to the data of sample hospitals, it is estimated that the sales volume of pemetrexed in 2016 is 1.13 billion yuan, with 12 enterprises in total, of which Jiangsu Haosen accounts for 34.1%, Qilu accounts for 32.3% and Lilly accounts for 20.4%; imatini's sales volume is 1.13 billion yuan, with 4 enterprises in total, including Novartis accounts for 86.7%, Haosen accounts for 9.9%, Zhengda Tianqing accounts for 3.2% and Shiyao accounts for 0.2%; gefitini The sales volume is 320 million yuan, including 2 enterprises, AstraZeneca and Qilu pharmaceutical approved in December 2016; the sales volume of doxorubicin is 282 million yuan, including 8 enterprises, among which stone pharmaceutical accounts for 52.3%, Shanghai Fudan Zhangjiang 38.2% and Changzhou Jinyuan 8.5% respectively; the sales volume of exetane is 240 million yuan, which is the exclusive product of Beida pharmaceutical industry; The sales volume of compound sodium cantharidate vitamin B6 is 164 million yuan, which is the exclusive product of Guizhou Baiqiang Pharmaceutical Co., Ltd.; the sales volume of dixitabin is 65.16 million yuan, with 6 enterprises in total The top three enterprises are pharmachmie accounting for 54.1%, Tianqing accounting for 28.7% and hausen accounting for 9.4% The main products used in digestive system are palonosetron, iprazole and dorasetron According to the data of sample hospitals, it is estimated that the sales volume of palonosetron in 2016 is 1.13 billion yuan, with 9 enterprises in total, including Qilu Pharmaceutical (Hainan) accounting for 44.8%, Tianqing accounting for 22.4%, Jiuyuan accounting for 17.1%, and other 6 accounting for 15.7%; the sales volume of eprazole is 120 million yuan, which is the exclusive product of Lizhu; the sales volume of doraseron is 120 million yuan, which is the exclusive product of Liaoning hisico The main products of nervous system drugs and mental disorders drugs are butylphthalide and pregabalin; the main products of mental disorders drugs are dexmedetomidine According to the data statistics of sample hospitals, the sales volume of butylphthalide in 2016 is expected to be 680 million yuan, which is the exclusive product of stone medicine Among them, the sales volume of capsule is 440 million yuan, and the sales volume of injection is 240 million yuan The sales volume of pregabalin is 42.67 million yuan At present, there are only two enterprises, Pfizer accounts for 87.0% and Chongqing Saiwei accounts for 13.0% It is estimated that in 2016, the sales volume of youmeituomi is 484 million yuan, and there are four enterprises in total The top three enterprises are Hengrui (90.5%), Guorui (5.6%), and Enhua (3.7%) The main anti infective drugs are tegacyclin, tenofovir and ertapenem According to the data of sample hospitals, it is estimated that the sales volume of tegacyclin in 2016 is 288 million yuan, with 7 enterprises in total, of which Wyeth accounts for 33.6%, hausen accounts for 25.5% and Haizheng accounts for 19.5%; tenofovir's sales volume is 110 million yuan, with 2 enterprises, namely Glaxo and Chengdu Beite pharmaceutical approved in November 2016; ertapenem The sales volume is 44.43 million yuan, which is the exclusive product of MSD The main products of immunomodulators are recombinant human tumor necrosis factor receptor antibody fusion protein and pegylated recombinant human granulocyte stimulating factor According to the data of sample hospitals, it is estimated that the sales volume of recombinant human tumor necrosis factor receptor antibody fusion protein in 2016 will be 288 million yuan, with three enterprises in total, including Shanghai CITIC Guojian, Shanghai SAIJIN biology, and Haizheng, accounting for 94.1%, 5.8% and 0.1%, respectively; pegylated recombinant human granulocyte stimulating factor The sales volume is 110 million yuan, and there are two enterprises in total Shandong granbeck (petrochemicals) accounts for 72.0% and Qilu 28.0% The main products of cardiovascular system drugs are pivastatin, olmesartan and levosimendan According to the data of sample hospitals, it is estimated that the sales volume of pivastatin in 2016 will be 157 million yuan, with 5 enterprises in total, the top three of which are CR double crane, Xinghe and Wanbang biochemistry, accounting for 75.1%, 16.7% and 5.4%; olmesartan's sales volume will be 109 million yuan, with 4 enterprises in total, the top three of which are respectively the first three co pharmaceuticals, accounting for 78.9%, Beijing Wansheng, 15.3% and Shanghai Xinyi, accounting for 3.4%; zuoximeng Dan The sales volume is 57.24 million yuan, and there are two enterprises in total, of which Qilu accounts for 96.6% and Chengdu shengnuo accounts for 3.4% In other fields, the main products of blood and hematopoietic system drugs are polysaccharide iron and agatraban; the drugs for endocrine and metabolic regulation are terlipressin; the drugs for bone and muscle are non bustard According to the data of sample hospitals, it is estimated that the sales volume of polysaccharide iron in 2016 will be 102 million yuan, with two enterprises in total, 55.1% of which are Schwarz and 44.9% of which are Qingdao Guofeng The sales volume of agaquban is 57.54 million yuan, which is the exclusive product of Tianjin Pharmaceutical Research Institute In the endocrine and metabolic regulation drugs, the sales volume of terlipressin was 96.57 million yuan, and there were two enterprises in total, Shenzhen Hanyu accounted for 75.0%, and Huiling accounted for 25% The sales volume of bone and muscle drugs for non Brescia is 64.24 million yuan, with three enterprises in total, including Jiangsu Wanbang, Hengrui and Hangzhou zhuyangxin pharmaceutical industries, accounting for 61.0%, 31.6% and 7.3%, respectively In the future, the market or the reconstruction of high-quality enterprise products to be able to enter the medical insurance catalog is the necessary condition for the rapid volume in the future, but not all the varieties to enter the medical insurance can become large varieties In order to become a large variety of market, the products of an enterprise should conform to the clinical path, have the advantages of pharmacoeconomics and the strong academic marketing ability of the enterprise Throughout the history, about half a year after the implementation of the new version of the medical insurance catalog, the competitive varieties of the provinces that have won the bid have started to enter a large-scale cycle, which generally takes three to five years for rapid growth However, the new health insurance payment method will have a greater impact on enterprise products In the future, large varieties with good curative effect will reconstruct the whole market.